HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 22, 2015 (HealthDay News) -- Functional magnetic resonance imaging (fMRI) might someday help psychiatrists quickly determine which antipsychotic drugs work best for patients with schizophrenia or bipolar disorder, according to research published online Aug. 28 in The American Journal of Psychiatry.
Anil Malhotra, M.D., director of psychiatry research at the Zucker Hillside Hospital in New York City, and colleagues at the Feinstein Institute for Medical Research in Manhasset, N.Y., used fMRI brain scans to develop a measurement of how well two regions of the brain communicate with each other. The level of communication correlated partly with how well psychotic patients improved when they took certain antipsychotic drugs. The researchers tried out the strategy on a group of 41 patients, aged 15 to 40, experiencing their first episode of acute psychosis. The patients underwent brain scans before they were randomly assigned to take risperidone or aripiprazole for a year.
Using information gained from that trial, the researchers tested their technique in 40 patients hospitalized for psychotic illness. Seventy-six percent of the time, the investigators successfully predicted the response of the second group of patients to drug treatments.
The researchers said they hope to improve that number to 80 percent. "We were close to these goals with the current work and are now looking to launch additional research in this area to hopefully increase this signal to those levels," Malhotra told HealthDay.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022